Cambrian Bio
Cambrian Bio (Cambrian BioPharma, Inc.) is a New York-headquartered clinical-stage drug development company working on the biology of aging. It runs a distributed "PipeCo" model — sourcing promising academic and early-stage science, then capitalizing and staffing each program as a separate subsidiary company under a shared development engine — to advance therapeutics that target the metabolic pathways that decline with age, first as treatments for chronic metabolic disease and ultimately as preventive medicines that extend healthspan. Its lead program, ATX-304, is an AMPK network activator with reported positive human translational data. Cambrian Bio is a therapeutics developer, not a software vendor: it publishes a corporate website, a science and pipeline overview, news and publications, and a blog, but no public API, developer portal, SDK, or machine-readable specification.
Cambrian Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Development, and Longevity.
Cambrian Bio’s developer surface includes engineering blog, product news, support, and 8 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 7
The organization behind the API
Scroll for all 7